Table 1.
Summary of investigational and available agents
| Generic | Brand | FDA indication | Company |
| Alefacept12 | Amevive | Treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy | Astellas |
| Alemtuzumab2 | Campath | Treatment of B-CLL | Berlex Laboratories |
| ASKP1240 | Not FDA approved | Astellas | |
| Azathioprine | Imuran | Adjunctive therapy in prevention of rejection of kidney transplants; management of active rheumatoid arthritis | Generic manufacturers |
| Basiliximab | Simulect | Prevention of acute rejection in kidney transplantation | Novartis |
| Belatacept | Nulojix | Prevention of acute rejection in renal transplant recipients | Bristol-Myers-Squibb |
| Bortezomib | Velcade | Treatment of multiple myeloma; treatment of relapsed or refractory mantle cell lymphoma | Millenium Pharmaceuticals |
| Cyclosporine | Neoral | Prevention of acute rejection in renal transplant recipients | Novartis |
| Eculizumab | Soliris | Treatment of PNH to reduce hemolysis and aHUS | Alexion Pharmaceuticals |
| Efalizumab12 | Raptiva | Management of moderate to severe chronic plaque psoriasis in adults | Genentech |
| Everolimus | Afinitor, Zortress | Treatment of advanced renal cell cancer (Afinitor®); treatment of subependymal giant cell astrocytom associated with tuberous sclerosis (Afinitor®); treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (Afinitor®); prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants (Zortress®) | Novartis |
| Mycophenolate Mofetil | Cellcept | Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal cardiac, or hepatic transplants | Genentech |
| Mycophenolate Sodium | Myfortic | Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal transplantation | Novartis |
| Horse or Rabbit anti-thymocyte Globulin | Atgam or Thymoglobulin | Treatment of corticosteroid resistant rejection in kidney transplantation | Pfizer/Sanofi |
| Rituximab | Rituxan | Treatment of CD20-positive non-Hodgkin’s lymphomas ; Treatment of moderately- to severely-active rheumatoid arthritis in adult patients with inadequate response to one or more TNF antagonists; Treatment of Wegener’s granulomatosis; Treatment of microscopic polyangiitis | Genentech |
| Sirolimus | Rapamune | Prevention of acute rejection in renal transplant recipients | Pfizer |
| Sotrastaurin, AEB-0711 | Not FDA approved | Novartis | |
| Tacrolimus | Prograf | Prevention of acute rejection in renal transplant recipients | Astellas |
| Tacrolimus Prolonged Release | Astragraf XL | Preventing organ rejection in kidney transplant recipients, as combination therapy with mycophenolate mofetil and corticosteroids, with or without tasiliximab induction | Astellas |
| Tolfacitinib1 | Xeljanz | Treatment of moderate to severe rheumatoid arthritis | Pfizer |
| Voclosporin | Not FDA approved | Isotechnika Pharma |
1
No longer being investigated for transplantation;
2
Withdrawn from United States Market. FDA: Food and Drug Administration; B-CLL: B-cell chronic lymphocytic leukemia; PNH: Paroxysmal nocturnal hemoglobinuria; aHUS: Atypical hemolytic uremic syndrome.